NCT04328844 2026-03-30A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic CancersiOncturaPhase 1 Active not recruiting210 enrolled
NCT04284774 2025-12-04Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialNational Cancer Institute (NCI)Phase 2 Active not recruiting5 enrolled 9 charts